Skip to content

Inform your strategic launch in Europe with this exclusive guide

Switzerland presents an attractive opportunity for biotech companies considering launching orphan drugs in Europe.

It’s the third-fastest country for reimbursing new medicines post-approval and recent regulatory changes look likely to speed this up even further.

Its regulatory independence from the EU, alongside its commitment to improving access to rare disease treatments, offers a unique opportunity.

  • The different types of access programs
  • The benefits and challenges for US biotechs
  • Patient expectations
  • Important factors to consider.

Download this exclusive guide to learn how to navigate the complex regulatory landscape of Switzerland and make sure your orphan drug reaches the patients who need it most.